Financial & SEC Reports

Here you will find a summary of Celldex Therapeutics, Inc.'s latest financial information.

Latest 10-Q

Form	Filing date	View
10-Q	Aug 5, 2021	View HTML 0001104659-21-100745.pdf EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA

Latest Annual Report and 10-K

Form	Filing date	View
10-K	Mar 29, 2021	View HTML 0001104659-21-043161.pdf EX-101.INS - XBRL INSTANCE DOCUMENT

Latest Proxy Statement

Form	Filing date	View
DEF 14A	Apr 27, 2021	View HTML 0001104659-21-055589.pdf
DEF 14A	Apr 28, 2020	View HTML 0001047469-20-002644.pdf

Data provided by Kaleidoscope.

FY = Fiscal Year. MRQ = Most Recent Quarter. mil = Millions. TTM = Trailing Twelve Months.

About us

Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.

Market Capitalization (Mil) $	2,421.70
Shares Outstanding (Mil)	46.48
Shares Outstanding, Average (FY) (Mil)	29.64
Float (Mil)	43.62

Investor Relations Contacts

Financial & SEC Reports

Latest 10-Q

Latest Annual Report and 10-K

Latest Proxy Statement

Share Related Items

About us

Our Pipeline